Why Lipocine Inc. [LPCN] Stock Can Charge Above The $1.66 Level

Lipocine Inc. [LPCN] has traded in a range of $0.30 to $2.39 in the last 1 year. As of this writing, the stock is at $1.66, up 7.79%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, LPCN shares are -3.14% down with the monthly amount drift of 19.38% and seems well in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 4, December 2020, Lipocine Provides New Regulatory Update on TLANDO™. According to news published on Yahoo Finance, Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it is continuing to work towards taking action on the TLANDO New Drug Application (“NDA”) during the week of December 7, 2020. However, the Company cannot assure that the FDA will act in that time frame.

Analyst Birdseye View:

The most recent analyst activity for Lipocine Inc. [NASDAQ:LPCN] stock was on January 11, 2018, when it was Downgrade with a Hold rating from Canaccord Genuity, which also lowered its 12-month price target on the stock from $11 to $2. Before that, on January 12, 2018, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $3. On December 08, 2017, H.C. Wainwright Resumed a Buy rating and boosted its price target on this stock to $10. On October 07, 2016, H.C. Wainwright Initiated a Buy rating and increased its price target to $25. On July 22, 2015, ROTH Capital Initiated a Buy rating and increased its price target to $36. On June 23, 2015, Canaccord Genuity Initiated a Buy rating and boosted its amount on this stock to $15.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.30 and a peak of $2.39. Right now, the middling Wall Street analyst 12-month amount mark is $3.00. At the most recent market close, shares of Lipocine Inc. [NASDAQ:LPCN] were valued at $1.66.


This publicly-traded organization’s revenue is $13,749 per employee, while its income is -$1,083,945 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -64.22, -165.47, -77.88 and -98.31 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 53.20 and the whole liability to whole assets at 36.36. It shows enduring liability to the whole principal at 28.39 and enduring liability to assets at 0.19 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.5100 points at 1st support level, the second support level is making up to 1.4800. But as of 1st resistance point, this stock is sitting at 1.5850 and at 1.6300 for 2nd resistance point.

Lipocine Inc. [LPCN] reported its earnings at -$0.07 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.06/share signifying the difference of -0.01 and -16.70% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.13 calling estimates for -$0.07/share with the difference of -0.06 depicting the surprise of -85.70%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Lipocine Inc. [NASDAQ:LPCN] is 4.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 60.38 and it’s amount to book ratio is 2.30.

Insider Stories

The most recent insider trade was by Higuchi John W., Director, and it was the purchase of 0.22 million shares on Mar 17. Patel Mahesh V., the CEO and President, completed a purchase of 40000.0 shares on Dec 31. On Dec 10, Patel Mahesh V., President and CEO, completed a purchase of 25000.0 shares.